Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh.

Md Jahidul Hasan Raihan Rabbani Ahmad Mursel Anam Shihan Mahmud Redwanul HuqMohammad Mufizul Islam PolashShahzadi Sayeeda Tun NessaSitesh Chandra Bachar

Published in: BMC infectious diseases (2021)

The daily high dose of baricitinib in severe COVID-19 results in early stabilization of the respiratory functions, declined requirements of critical care supports, reduced rehospitalization with mortality rate compared to its daily usual dose.

Keyphrases

high dose
coronavirus disease
sars cov
low dose
stem cell transplantation
early onset
physical activity
cardiovascular events
respiratory syndrome coronavirus
risk factors
type diabetes
coronary artery disease